JDRF and ada fundraising promise inconsistent with actual spending

October 2, 2019

This is the eighth annual review of advertising messages used by the ADA and JDRF at national fundraising events. During 2019, the ADA and JDRF advertised for a total of 231 national events including walks, rides, and galas. Click here to read more.


Cure Research Remains the Primary Reason People Participate in T1D Fundraising Walks

September 25, 2019

The primary purpose of this survey is to identify the main reasons people in the T1D community participate in JDRF or ADA diabetes fundraising walks. The leading finding is that walk participants want the money they raise to be used for T1D cure research above all else. Click here to read more.


JDRF LAUNCHES NORTHERN CALIFORNIA CENTER OF EXCELLENCE TO ACCELERATE BREAKTHROUGHS TO CURE T1D

September 12, 2019

On September 4th JDRF announced the launch of the JDRF Northern California Center of Excellence in partnership with Stanford and the University of California San Francisco (UCSF). Click here to read more.


Semma Therapeutics Acquired by Vertex Pharmaceuticals for $950m

September 5, 2019

On September 3rd, Vertex Pharmaceuticals Incorporated announced an agreement to purchase Semma Therapeutics, one of the most promising and advanced companies developing components to a Practical Cure, for $950 million in cash. Click here to read more.


JDRF INFOGRAPHIC: 2/3 OF JDRF REVENUE NEVER MAKES IT TO T1D RESEARCH

August 27, 2019

This infographic explains how JDRF, the largest and most influential diabetes fundraising organizations in the U.S., uses its funds. Click here to read more.


T1D Board of Directors: It’s Time for Change

August 21, 2019

As the highest governing body, the Board of Directors at the major T1D non-profits are responsible for establishing the organization mission and values, setting the strategic direction, overseeing executive leadership, and allocating resources. Click here to read more.


Executive Compensation at Major T1D Nonprofits Still Not Tied to Cure Progress

August 12, 2019

This is the eighth annual review of executive compensation for the top diabetes non-profits. The review focuses on the ADA and JDRF, the largest diabetes fundraising organizations, but also includes data for Joslin and the Diabetes Research Institute Foundation (DRIF). Click here to read more.


ADA INFOGRAPHIC: ONLY 2.4% OF INCOME GOES TO T1D RESEARCH

August 6, 2019

This infographic provides a snapshot of how the ADA, one of the largest and most influential diabetes fundraising organizations in the U.S., uses its funds. Click here to read more.


nih t1d funding cut in half

July 15, 2019

This report provides an overview of type 1 diabetes research funding at the National Institutes of Health (NIH) in 2018. In preparing this report, the JDCA reviewed and categorized all NIH grants into three distinct categories: type 1 focused; type 2 focused; and general diabetes. Click here to read more.


ADA 2018: Only 2.4% of Income Dedicated to T1D Research Grants

June 20, 2019

Last week, the American Diabetes Association (ADA) released their audited financial statements for 2018. This is the seventh year that we have reviewed these financial documents and little has changed. Click here to read more.


Update on the American Diabetes Association's 79th Sessions

June 11, 2019

The American Diabetes Association's 79th Scientific Sessions, the largest annual American diabetes research conference of the year, was held June 7-11 in San Francisco. Click here to read more and view conference highlights.


JDRF Research Grant Allocation

June 6, 2019

This report reviews every grant funded by JDRF during 2018, 451 projects in total. The 451 research project abstracts are individually categorized by research type and development level. Click here to read more.


Practical Cure Projects in Human Trials by Pathway

May 23, 2019

This report reviews the 11 active Practical Cure (PC) research projects underway in FDA approved human clinical trials. No projects have been abandoned since our last review in the 2018 State of the Cure and two new projects have been added to the list. Click here to read more.


An Open Letter to JDRF with Four Key Recommendations

May 21, 2019

This report outlines four key recommendations for the JDRF Board of Directors and the new CEO to consider during their planning process for the upcoming fiscal year. These recommendations are based upon the priorities and wishes of the T1D community as demonstrated in semi-annual JDCA surveys. Click here to read more.


A Practical Cure for T1D: The Four Research Pathways

May 13, 2019

A Practical Cure is any solution which minimizes the disruptive aspects of T1D, delivers a near-normal quality of life and has a chance to be available within the next 15 years. It is aligned with the wishes and desires of people who are currently living with type 1 diabetes. Click here to read more.


T1D Research Trials Throughout the World

May 2, 2019

This is the seventh annual review of all active type 1 diabetes trials currently in human testing. This year, in addition to all clinical trials active in the US, we also included trials listed in the official registries of the EU, Australia, China, Japan, and India. Click here to read more.


JDRF T1D Fund Two-Year Retrospective

April 19, 2019

The JDRF T1D Fund was launched as a subsidiary of JDRF in December 2016. This report examines the Fund's impact on T1D research over the past two years. Click here to read more.


Aaron Kowalski Named JDRF President and CEO

April 9, 2019

This report provides a quick update on JDRFs new President and CEO, Aaron Kowalski. Click here to read more.


Practical Cure Update: ViaCyte

April 4, 2019

This report focuses on ViaCyte’s islet cell replacement therapies, identified as a Practical Cure in the 2018 State of the Cure for T1D, and features an interview with ViaCyte president and CEO Paul Laikind. Click here to read more.


JDRF Payroll Doubled while Research Grant Spending Cut in Half Over Past Decade

March 25, 2019

This report examines JDRF's Payroll Expenses, which includes salaries, bonuses, and all other staffing expenses. Click here to read more.


T1D Financial Donor Priority Survey: Cure Research Remains #1

March 14, 2019

This is the seventh annual survey-based report on the giving priorities of T1D donors. The key takeaway is the same as all prior years: the number one reason people make donations to diabetes charities and/or participate in fundraising activities such as walks and galas is to find a cure. Click here to read more.


JDRF Internal Costs for Administering Research Grants

March 7, 2019

This is a third in a series of reports on JDRF financials. The main takeaway is that JDRF administration cost for each dollar of actual research grants have increased 350 percent since 2008 while research grant spending is down 50 percent. Click here to read more.


2018 JDRF Revenue and Expenses Overview

February 21, 2019

This report provides an overview of JDRF's 2018 revenue and expenses, released last week. Based on publicly available tax and financial documents, it shows how JDRF generates its revenue and how it utilizes those funds. Click here to read more.


2018 JDRF Financials in Three Charts

February 14, 2019

This report provides an overview of JDRF's 2018 financial statements, released this week. Based on publicly available tax and financial documents, it show how JDRF generates its revenue and how it utilizes those funds. Click here to read more. 


encapsulation: an overview of competitors

January 22, 2019

This report will review the evolution of encapsulation therapies and examine all companies currently developing encapsulation devices. Encapsulation is a form of cell transplantation, one of the four JDCA Practical Cure Pathways. Click here to read more.


2018 State of the cure for type 1 diabetes

January 14, 2019

This is the seventh annual addition of this report. It summarizes progress made during 2018 toward a Practical Cure for type 1 diabetes. Click here to read more.